Home > Resources > Company Profiles > Alcon, Inc. > News

Alcon, Inc. (ACL)

Your Name

Your Email Address *
Send a copy to me

Recipient's Email Address *

Separate multiple email addresses (max 20) with commas.

Subject *

Message

0/1500

Email Confirmation

Cary R. Rayment , CEO/Chairman of the Board/President/Director

www.alconinc.com

Industry: Healthcare

OPEN

LAST

PREV CLOSE

CHANGE

VOLUME

Overview

News

People

Financials

Overview

A global medical specialty company, that develops, manufactures and markets pharmaceuticals, surgical equipment & devices and consumer eye care products to treat primarily diseases & disorders of the eye.

Portfolio Articles

Eye on a Huge Deal
Novartis in a $39 billion transaction with Nestlé.
Apr 07 2008
Pharma's Fees
How the big drugmakers tend to your doctor.
Nov 19 2007

See more news on this company

News Feeds

Alcon breaks ground on W.Va. site expansion AP
Sep 19 2008

Portfolio Blogs

Eyeball Datapoint of the Day
Apr 07 2008

Press Releases

Alcon Plans to Expand Manufacturing Facility in West Virginia Sep-19-2008, 11:00AM EDT
Research and Markets: Comprehensive Report into Alcon Inc Medical Equipment Company is Essential Reading for Those in the Industry Sep-16-2008, 07:01AM EDT
Alcon Launches New AcrySof(R) ReSTOR(R) Intraocular Lens for Presbyopia Outside the U.S. Sep-15-2008, 12:00AM EDT
Alcon Expands Refractive Surgery Options with the Introduction of the AcrySof(R) Phakic Intraocular Lens Outside the U.S. Sep-12-2008, 12:00AM EDT
The Alcon Research Institute Recognizes Seven Top Researchers in Ophthalmology with Unrestricted Grants Aug-21-2008, 05:30PM EDT

News From Around the Web

News

Novartis CEO visits Alcon (Fort Worth Star-Telegram, Texas)

Oct 10 2008
On W.Va. 2, deer herds and the Main Street economy (Herald-Dispatch, West Virginia)

Oct 09 2008
Studios prep major film production (Variety)

Oct 08 2008
Standardized digital imaging technique aims to increase understanding of intralenticular glistenings (Modern Medicine)

Oct 08 2008
Alcon to expand manufacturing facility in West Virginia (Modern Medicine)

Sep 29 2008
Fertility: Antidepressants may hurt sperm (Health.com)

Sep 26 2008
Alcon breaks ground on W.Va. site expansion (Boston Globe)

Sep 19 2008
Alcon to create 186 jobs at Cork plant (Emigrant Online, Ireland)

Sep 18 2008
Alcon showcases new phakic lens (Modern Medicine)

Sep 15 2008
186 new jobs for Cork (Emigrant Online, Ireland)

Sep 14 2008

Employees

Number of Employees: 14,500

Revenue per Employee: $396,652

Top Executives

Ed McGough, Senior VP, Subsidiary

Stefan Basler, Other Corporate Officer

Joanne Beck, General Manager

Martin Schneider, Other Corporate Officer

Richard J. Croarkin, CFO/Senior VP, Divisional

Dr. Gerald D. Cagle, Senior VP, Subsidiary/Other Executive Officer

Elaine E. Whitbeck, General Counsel/Secretary/Senior VP, Subsidiary/Other Executive Officer

Kevin J. Buehler, Senior VP, Subsidiary/Other Executive Officer

Board of Directors

Lodewijk J.R. de Vink, Director

Francisco Castaner, Director/Vice Chairman

Gerhard N. Mayr, Director

Thomas G. Plaskett, Director

Elaine E. Whitbeck, General Counsel/Secretary/Senior VP, Subsidiary/Other Executive Officer

Dr. Werner J. Bauer, Director

Joseph M. Weller, Director

Paul Polman, Director

Financials

Quarterly

Annual

Income Statement	09/2008	04/2008	02/2008	10/2007
Sales	381.4 Mil.	346.3 Mil.	331.1 Mil.	174.8 Mil.
Gross Operating Profit	1.35 Bil.	1.19 Bil.	1.14 Bil.	1.16 Bil.
Operating Income before D & A (EBITDA)	684.7 Mil.	561 Mil.	537 Mil.	626.2 Mil.
Total Income Before Interest Expenses (EBIT)	663.6 Mil.	520.9 Mil.	517.3 Mil.	482.6 Mil.
Total Net Income	566.4 Mil.	429.4 Mil.	376.5 Mil.	415.3 Mil.
Basic EPS, Total	1.9	1.44	1.27	1.39
Diluted EPS, Total	1.88	1.43	1.27	1.38

BALANCE STATEMENT	09/2008	04/2008	02/2008	10/2007
Cash and Equivalents	2.24 Bil.	2.5 Bil.	2.13 Bil.	826.9 Mil.
Total Assets	5.16 Bil.	5.38 Bil.	4.82 Bil.	3.5 Bil.
Total Liabilities	2.8 Bil.	2.9 Bil.	2.86 Bil.	1.9 Bil.
Total Capitalization	3.92 Bil.	3.99 Bil.	3.43 Bil.	3.1 Bil.

Cash Flow	09/2008	04/2008	02/2008	10/2007
Net Cash From Continuing Operations	1.07 Bil.	398.1 Mil.	1.47 Bil.	814.7 Mil.
Net Cash From Investing Activities	-149.5 Mil.	-68.6 Mil.	-227.1 Mil.	-63.3 Mil.
Net Cash From Financing Activities	-825.9 Mil.	31.3 Mil.	-606.6 Mil.	-1.42 Bil.
Net Change in Cash & Cash Equivalents	102.5 Mil.	365.4 Mil.	645.1 Mil.	-662.3 Mil.

Income Statement	2008	2007	2006	2005
Sales	1.24 Bil.	1.06 Bil.	950.9 Mil.	956 Mil.
Gross Operating Profit	4.36 Bil.	3.84 Bil.	3.42 Bil.	2.96 Bil.
Operating Income before D & A (EBITDA)	2.1 Bil.	1.93 Bil.	1.4 Bil.	1.33 Bil.
Total Income Before Interest Expenses (EBIT)	2 Bil.	1.66 Bil.	1.24 Bil.	1.15 Bil.
Total Net Income	1.59 Bil.	1.35 Bil.	931 Mil.	871.8 Mil.
Basic EPS, Total	5.32	4.43	3.04	2.85
Diluted EPS, Total	5.25	4.37	2.98	2.8

BALANCE STATEMENT	2008	2007	2006	2005
Cash and Equivalents	2.13 Bil.	1.49 Bil.	1.46 Bil.	1.09 Bil.
Total Assets	4.82 Bil.	3.46 Bil.	3.27 Bil.	2.64 Bil.
Total Liabilities	2.86 Bil.	2 Bil.	2.28 Bil.	1.88 Bil.
Total Capitalization	3.43 Bil.	2.96 Bil.	2.61 Bil.	2.26 Bil.

Cash Flow	2008	2007	2006	2005
Net Cash From Continuing Operations	1.47 Bil.	1.41 Bil.	1.24 Bil.	1.05 Bil.
Net Cash From Investing Activities	-227.1 Mil.	-166.1 Mil.	-382.3 Mil.	-255.5 Mil.
Net Cash From Financing Activities	-606.6 Mil.	-1.22 Bil.	-433 Mil.	-822.7 Mil.
Net Change in Cash & Cash Equivalents	645.1 Mil.	32 Mil.	363.8 Mil.	7.4 Mil.

Alcon, Inc. (ACL)

Company Information

Overview

Employees

Top Executives

Board of Directors

Financials

Company Profile Change Request